Halozyme Therapeutics Inc (HALO)

Return on assets (ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	444,091	392,467	337,293	318,802	281,594	253,908	233,705	181,636	202,129	211,197	366,150	434,923	402,710	409,104	228,724	163,083	129,085	21,524	-39,698	-80,139
Total assets	US$ in thousands	2,063,480	2,118,030	1,969,450	1,841,530	1,733,270	1,892,660	1,810,440	1,699,450	1,841,510	1,864,540	1,781,390	1,162,250	1,104,430	1,185,420	1,025,860	966,582	579,924	524,029	526,997	492,353
ROA		21.52%	18.53%	17.13%	17.31%	16.25%	13.42%	12.91%	10.69%	10.98%	11.33%	20.55%	37.42%	36.46%	34.51%	22.30%	16.87%	22.26%	4.11%	-7.53%	-16.28%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $444,091K ÷ $2,063,480K
= 21.52%

Halozyme Therapeutics Inc's return on assets (ROA) has shown significant variation over the analyzed periods. The ROA was negative in early 2020, signaling that the company's assets were not generating sufficient profits at that time. However, there was a notable improvement throughout 2020 and 2021, with ROA turning positive and increasing steadily. By the end of 2021, the ROA reached a relatively high level of 36.46%.

Subsequently, in the first half of 2022, the ROA declined but remained above 10%. From mid-2022 to the end of 2024, the ROA fluctuated within a range of around 10% to 21.52%. Overall, the positive trend in ROA seen in 2020 and 2021 indicates an improvement in the company's ability to generate profits from its assets, although there was some variability in the following periods. Further analysis and comparison with industry benchmarks would provide additional insights into Halozyme Therapeutics Inc's performance.